Navigation Links
AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer
Date:1/11/2011

WILMINGTON, Del. and NASHVILLE, Tenn., Jan. 11, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) and Sarah Cannon Research Institute (SCRI), an international leader in advancing therapies for cancer patients through clinical research, today announced that SCRI will lead the clinical development of a novel targeted oncology compound from AstraZeneca.

Cancer is a major cause of mortality globally; accounting for 7.4 million (or 13%) of all deaths in 2004. The World Health Organization estimates the incidence of cancer to continue rising to reach an estimated 9.2 million deaths in 2015, driving the critical need for novel therapies to reach patients quickly and efficiently.

Under the agreement, SCRI will collaborate with AstraZeneca to provide clinical program development expertise, clinical program design, medical oversight and trial management. The first clinical trial to be conducted under the agreement was initiated in November 2010 with the first patient enrollment into that clinical trial on November 23, 2010.  

Potential benefits to be derived from this unique collaboration include enhanced strategic clinical development in pursuit of new and more effective cancer therapies, flexibility in program design and implementation, innovation via realizing efficiencies across the collaboration, leveraging the strengths of the innovative collaboration, and rapid patient enrollment to clinical trials through the access of a large network of cancer patients.  

Andrew Hughes, Vice President, Oncology Clinical Innovative Medicines, said: "AstraZeneca has a long history of discovering and developing cancer therapeutics that have made a real difference to cancer patients. For many years we have enjoyed an excellent working relationship with SCRI and this is an exciting next step in our relationship that continues to foster collaboration and innovation in advan
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
2. Rigel Earns Milestone Payments From AstraZeneca
3. TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis
4. AstraZeneca Outlines Principles for Product-Related Online Communications
5. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
6. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
7. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
8. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
9. BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
10. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
11. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and his ... to participate in an investigational study of donor stem ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ... current investigational study must be older than nine months, ...
(Date:8/29/2014)... August 29, 2014 Due to a misstatement ... week, the Adult Stem Cell Technology Center, LLC ( ASCTC ... stem cell therapy research that might benefit ALS patients. ... for new stem cell technologies and therapeutic applications, FRC listed ... Bucket Challenge donors who wish not to support research ...
(Date:8/29/2014)... TX (PRWEB) August 29, 2014 ... ISO 13485:2003 certified, GAMP® 5 compliant imaging core ... an international Phase II clinical trial to assess ... , Throughout this trial, Intrinsic Imaging will provide ... limited to, protocol and charter development, site qualification, ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Research Park MADISON OpGen, Inc. has added ... and Thomas Pyle. The company is looking to bring in ... level, according to Dan Broderick, managing director of Mason ... of experience with company operations and product positioning, Broderick said. ...
... released Q2 MoneyTree Survey figures show no reported ... June of this year. Both total venture capital ... survey, which was released by PricewaterhouseCoopers, Thomson Venture ... other states also showed $0 activity. , ,The ...
... -- PointOne Systems , a company specializing ... chosen Frank Langely as its president and chief ... recently served as president and CEO of ... The company develops molecular biology and serologic products ...
Cached Biology Technology:OpGen adds Thomas Pyle and James Ogle to board of directors 2MoneyTree Survey reports no venture investment activity in Wisconin in Q2 2MoneyTree Survey reports no venture investment activity in Wisconin in Q2 3MoneyTree Survey reports no venture investment activity in Wisconin in Q2 4MoneyTree Survey reports no venture investment activity in Wisconin in Q2 5MoneyTree Survey reports no venture investment activity in Wisconin in Q2 6
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... - In a cell,s nucleus, chromosomal DNA is ... an amalgam biologists call chromatin. Until about two ... "sidekick," the mere packing material around which the ... have developed a greater appreciation for how DNA/histone ... from multiple research institutions studying the sequence of ...
(Date:8/28/2014)... identified a handful of bacterial culprits that may drive ... ulcerative colitis, using patients, own intestinal immune responses as ... in the journal Cell . , Trillions of ... a critical role in the development and progression of ... of bacterial species affect a person,s susceptibility to IBD ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Yale study identifies possible bacterial drivers of IBD 2
... a man-made wetland in Ohio for two years concluded that ... or better than would a natural marsh. , The wetland, ... phosphorus by nearly 60 percent and nitrates by 40 percent. ... in water pollution. , High levels of these nutrients can ...
... after it burst onto the scene, HIV/AIDS has claimed ... societies around the world, particularly in Africa and other ... after years of effort AIDS researchers succeeded in developing ... effective against AIDS. By blocking the activity of the ...
... Children's Fund (UNICEF) today announced that countries are on target ... the end of this year. Global measles deaths have plummeted ... 530 000 in 2003. , The largest reduction occurred in ... where estimated measles deaths decreased by 46%. , "Progress of ...
Cached Biology News:Man-made wetland's effectiveness similar to natural marsh 2Man-made wetland's effectiveness similar to natural marsh 3Supercomputers to focus brains on AIDS dilemma 2Supercomputers to focus brains on AIDS dilemma 3Supercomputers to focus brains on AIDS dilemma 4Measles Deaths Worldwide Drop By Nearly 40% Over Five Years 2
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
BAI-1 (T-20)...
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
... Immunogen: Synthetic peptide derived from the ... rat ZO-1. Specificity: Specific for the ... Reactivity: Human Dog Rat Mouse (positive ... frozen mouse liver heart blood vessel and ...
Biology Products: